bioRxivImmunologyPreprint
The HLA Ligand Atlas - A resource of natural HLA ligands presented on benign tissues
Ana Marcu, Leon BichmanniD, Leon Kuchenbecker, Daniel Johannes Kowalewski, Lena Katharina Freudenmann, Linus Backert, Lena Mühlenbruch, András Szolek, Maren Lübke, Philipp Wagner, Tobias Engler, Sabine Matovina, Jian Wang, Mathias Hauri-Hohl, Roland Martin, Konstantina Kapolou, Juliane Sarah WalziD, Julia Velz, Holger Moch, Luca Regli, Manuela Silginer, Michael WelleriD, Markus W. Löffler, Florian Erhard, Andreas Schlosser, , Marian Christoph NeidertiD
Abstract
The human leukocyte antigen (HLA) complex controls adaptive immunity by presenting defined fractions of the intracellular and extracellular protein content to immune cells. Here, we describe the HLA Ligand Atlas, an extensive collection of mostly matched HLA-I and -II ligandomes from 225 benign samples (29 tissues, 21 subjects). The initial release covers 51 HLA-I and 86 HLA-II allotypes presenting 89,853 HLA-I- and 140,861 HLA-II ligands. We observe that the immunopeptidomes differ considerably between tissues and individuals on both source protein and HLA-ligand level. 1,407 HLA-I ligands stem from non-canonical genomic regions. We highlight the importance of comparatively analyzing both benign and malignant tissues to inform tumor association, based on a case study in three glioblastoma patients. The resource provides insights into applied and basic immune-associated questions in the context of cancer immunotherapy, infection, transplantation, allergy, and autoimmunity. It is publicly available at www.hla-ligand-atlas.org.
- organism: human
- assay: proteomics
- research focus: cell type annotation
- research focus: cell-cell communication
- research focus: differential expression
- research focus: gene regulatory network inference
- approach: experimental assay
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Gene and protein sequence features augment HLA class I ligand predictions
K. Bresser, B. Nicolet, … T. Schumacher·bioRxiv·Sep 3, 2023
- NeoOmni Atlas: an integrated database for pan-cancer neoantigen derived from proteogenomics analysis
Tao Zheng, Zhi Ran, … Haodong Xu·bioRxiv·Oct 16, 2026
- Negative trade-off between neoantigen repertoire breadth and the specificity of HLA-I molecules shapes antitumour immunity
M. Manczinger, G. Balogh, … C. Pal·bioRxiv·Jun 25, 2020
- Immunogenicity of non-canonical HLA-tumor ligands identified through proteogenomics
M. Lozano-Rabella, A. Garcia-Garijo, … A. Gros·Clinical Cancer ResearchPeer-reviewed·Feb 7, 2023
- Validation of a high-performance liquid chromatography-tandem mass spectrometry immunopeptidomics assay for the identification of HLA class I ligands suitable for pharmaceutical therapies
M. Ghosh, M. Gauger, … S. Stevanovic·bioRxiv·Oct 29, 2019
- Single cell spatial analysis and biomarker discovery in Hodgkin lymphoma
A. M. Xu, A. Jiang, … A. Merchant·bioRxiv·May 24, 2023